Hong Kong 67%; Thailand 59%

Celltrion is strengthening its position in major Asian markets, including Malaysia, Singapore and Thailand, by maintaining the No. 1 position in prescriptions for its flagship products. After boosting its market share through a direct sales strategy run by local subsidiaries, the company is also expanding the number of countries where it launches high-margin follow-on products.

Celltrion's factory in Yeonsu-gu, Incheon. The Asia Business Daily archive.

Celltrion's factory in Yeonsu-gu, Incheon. The Asia Business Daily archive.

View original image

According to IQVIA, a pharmaceutical market research firm, Celltrion's autoimmune disease treatment Remsima product line, available as intravenous and subcutaneous injections, maintained the No. 1 position in prescriptions in the second quarter of this year, with market shares of 95% in Singapore, 83% in Hong Kong and 75% in Malaysia.


Celltrion also maintained its lead in oncology. Herzuma, a treatment for breast and stomach cancer with the active ingredient trastuzumab, recorded market shares of 67% in Hong Kong, 59% in Thailand and 52% in Malaysia. In Thailand in particular, its share rose 17 percentage points from the previous quarter to 59%, widening the gap with competing products. Truxima, a blood cancer treatment with the active ingredient rituximab, recorded market shares of 92% in Singapore, 78% in Thailand and 41% in Hong Kong.


Vegzelma, a treatment for metastatic colorectal and breast cancer with the active ingredient bevacizumab, is growing rapidly in Malaysia. After ranking fourth in Malaysia's bevacizumab market in the fourth quarter of last year, Vegzelma rose to first place in the first quarter of this year and held the lead in the second quarter with a 25% market share.


The company's locally tailored direct sales strategy, which reflects the characteristics of each market, is cited as a key factor behind these results. The company has continued to secure contracts in Asia's tender-driven markets by leveraging its product competitiveness and reliable supply capabilities, while building trust by responding quickly to the needs of healthcare institutions.


Celltrion is expanding the sales regions for its follow-on products by leveraging the sales networks built around its existing products. Since late last year, the company has successively launched Omlyclo, an allergy treatment with the active ingredient omalizumab, and Steqeyma, an autoimmune disease treatment with the active ingredient ustekinumab, in Singapore and Malaysia, among other markets. It plans to launch Vegzelma in Hong Kong at the end of November and Stoboclo, a treatment for bone disease with the active ingredient denosumab, in Thailand in December. In February 2027, the company plans to launch Eydenzelt, an ophthalmic treatment with the active ingredient aflibercept, in Singapore and Omlyclo in Thailand.



A Celltrion representative said, "Our major product lines, including Remsima, are maintaining high market shares in Asia and strengthening our position in the region. We will leverage the direct sales capabilities of our local subsidiaries and the value of our brands to establish our high-margin follow-on products in the market at an early stage."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing